Neutrolis Inc
Sean McElduff has extensive work experience in various financial roles. Sean currently serves as the CFO at Chew, a food innovation lab that focuses on creating nutritious and sustainable packaged food products. Prior to this, Sean held the position of CFO at Fastfood, a company specializing in the fast food industry.
Before their roles at Chew and Fastfood, Sean worked as the CFO at Neutrolis Inc, a position they held from 2020 onwards. Sean also served as a Startup CFO at Countsy, a company that provides accounting and HR services to venture-backed startups.
Earlier in their career, Sean worked as the Chief Financial Officer and Chief Operating Officer at BouncePilot, a company offering email retargeting for eCommerce. Sean also held the position of Chief Financial Officer & Controller at Bevi, a company that revolutionizes the beverage supply chain through their water purification and customized drink machines.
Sean's work experience also includes roles at TJX Companies, Jefferies & Company, Wachovia Securities, and Marlin & Associates in various finance and M&A positions.
Overall, Sean McElduff has a diverse background in finance and has gained extensive experience in financial leadership roles across different industries.
From 2003 to 2005, Sean McElduff attended Columbia Business School, where they obtained a Master of Business Administration (MBA) degree. During this time, they primarily focused on studying Finance & Economics and International Business.
This person is not in any teams
This person is not in any offices
Neutrolis Inc
Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. Although NETs represent one of the most important immunology discoveries in the past 20 years, there is no therapyon the market that effectively targets and removes NETs. Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that effectively removes NETs and halt their pathologic effects on end-organs. Neutrolis has a strong patent portfolio for new molecular entity and method of use. The lead molecule, NTR-441, is slated to enter clinical trials in 2021.